{"nctId":"NCT00883233","briefTitle":"Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in Acne Vulgaris","startDateStruct":{"date":"2009-04"},"conditions":["Acne"],"count":123,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Adapalene-BPO 3-hour daily application before bedtime"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Adapalene-BPO Gel every other day application"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion"]},{"label":"4","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Adapalene BPO Gel standard daily overnight application"]}],"interventions":[{"name":"Adapalene BPO Gel standard daily overnight application","otherNames":["Standard"]},{"name":"Adapalene-BPO 3-hour daily application before bedtime","otherNames":["3-hour before bedtime"]},{"name":"Adapalene-BPO Gel every other day application","otherNames":["every other day"]},{"name":"Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion","otherNames":["Adapalene-BPO Gel with Cetaphil® Moisturizing Lotion"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female Subjects of any race, aged 12 to 35 years inclusive\n* Subjects with mild or moderate facial acne vulgaris\n* Subjects with skin phototype I to IV\n\nExclusion Criteria:\n\n* Subjects with more than 1 nodules or cysts on the face,\n* Subjects with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.)","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"35 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Local Tolerability Was Analyzed in Terms of Worst Score Post-Baseline.","description":"Total Sum Score (TSS) is the sum of the 4 local tolerability scores for dryness, erythema, scaling and stinging/burning evaluated at each visit \\[None=0, Mild=1, Moderate=2 and Severe=3\\]. In consequence, it ranges from 0 \\[better outcome\\] to 12 \\[worse outcome\\]and was calculated for each study visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.23","spread":"2.04"},{"groupId":"OG001","value":"3.06","spread":"1.92"},{"groupId":"OG002","value":"3.25","spread":"2.05"},{"groupId":"OG003","value":"4.13","spread":"2.45"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":32},"commonTop":["nasopharyngitis","erythema","headache","sunburn","dermatitis contact"]}}}